Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
Early changes in serum PRO-C6 predict lung function trajectories in IPF
August 28, 2026
Early changes in serum PRO-C6 predict lung function trajectories in idiopathic pulmonary fibrosis
Introduction
Extracellular matrix remodeling is central to idiopathic pulmonary fibrosis (IPF) pathology and progression. Especially remodeling of type VI collagen (COL6) has been linked to disease severity and progression. COL6 synthesis releases the neoepitope PRO-C6, which includes the signaling peptide endotrophin, that has pro-fibrotic effects and may bind to and activate platelets. Thus, serum PRO-C6 may be a candidate surrogate endpoint in clinical trials of IPF. Currently, there are no reliable tools to predict lung function trajectories.
The aim of this study was to evaluate the prognostic ability of assessing early changes in serum PRO-C6 for predicting future lung function trajectories in IPF.
Poster
Conclusion
This study found that increases in serum PRO-C6 were prognostic for future FVC decline, suggesting that PRO-C6 dynamics may identify high risk patients and could be a surrogate endpoint in clinical trials and a tool to improve patient care.
